Antoni Ribas
University of California, Los Angeles · 1,741 works · 165,006 citations · h-index 159
Top works
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- Cancer immunotherapy using checkpoint blockade
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)